Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
20 Giugno 2024 - 1:00PM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, today announced that
management will participate in a corporate presentation at
the H.C. Wainwright 5th Annual Neuro Perspectives Conference,
being held virtually on Thursday, June 27, 2024.
A webcast of the presentation will be available on the “Events
& Presentations” page at 7:00 a.m. ET within the Investors
section of the Alector website
at http://investors.alector.com. A replay will be available on
the Alector website for 90 days following the event.
About AlectorAlector is a clinical-stage
biotechnology company pioneering immuno-neurology, a novel
therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a root
cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and seek to treat
indications, including Alzheimer’s disease and genetically defined
frontotemporal dementia patient populations. Alector is
headquartered in South San Francisco, California. For additional
information, please visit www.alector.com.
Alector Contacts:
AlectorKatie Hogan202-549-0557katie.hogan@alector.com
1AB (media)Dan Budwick973-271-6085 dan@1abmedia.com
Argot Partners (investors)Laura
Perry212.600.1902alector@argotpartners.com
Grafico Azioni Alector (NASDAQ:ALEC)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Alector (NASDAQ:ALEC)
Storico
Da Dic 2023 a Dic 2024